Bioplatin AG is a trading company dealing in various commodities, particularly pharmaceutical and medical products, and in the acquisition and use of licences. Its principal project is Dicycloplatin (DCP), a platinum‑based anti‑tumour agent described on the website with Phase I clinical information and patent protection in multiple markets.
AI-generated
Offering
Products & services
Industry:Research & Development
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Anti-tumor agent based on platinum for the treatment of cancer cells; described as a new active ingredient for bronchial carcinoma and liver cancer, with Phase I results and low toxicity.
DCP patent and licence rights
Acquisition and use of licence and protection rights for DCP; worldwide patent protection is mentioned, as well as interest from pharmaceutical companies in an in-licensing.
Comparisons
Bioplatin AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank Bioplatin AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once Bioplatin AG has claimed this profile, we'll publish editorial articles and case studies here together.